[{"address1": "680 East Colorado Boulevard", "address2": "Suite 180", "city": "Pasadena", "state": "CA", "zip": "91101", "country": "United States", "phone": "631 830 7092", "fax": "631 982 5050", "website": "https://lixte.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.", "fullTimeEmployees": 2, "companyOfficers": [{"maxAge": 1, "name": "Mr. Bastiaan  van der Baan M.Sc.", "age": 52, "title": "President, Chief Scientific Officer & Director", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 172784, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert Neal Weingarten", "age": 72, "title": "CFO, VP & Secretary", "yearBorn": 1952, "fiscalYear": 2023, "totalPay": 175000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Geordan G. Pursglove", "age": 36, "title": "CEO & Chairman", "yearBorn": 1988, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Johannes Henricus Matthias Schellens M.D., Ph.D.", "age": 67, "title": "Consultant & Chief Medical Officer", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.02, "open": 3.01, "dayLow": 2.4401, "dayHigh": 4.25, "regularMarketPreviousClose": 2.02, "regularMarketOpen": 3.01, "regularMarketDayLow": 2.4401, "regularMarketDayHigh": 4.25, "payoutRatio": 0.0, "beta": 0.368, "volume": 64132966, "regularMarketVolume": 64132966, "averageVolume": 1922516, "averageVolume10days": 11585150, "averageDailyVolume10Day": 11585150, "bid": 2.7, "ask": 2.79, "bidSize": 1, "askSize": 1, "marketCap": 7802281, "fiftyTwoWeekLow": 0.64, "fiftyTwoWeekHigh": 4.25, "fiftyDayAverage": 1.2546, "twoHundredDayAverage": 1.6495, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 4544390, "profitMargins": 0.0, "floatShares": 2527941, "sharesOutstanding": 2756990, "sharesShort": 4456, "sharesShortPriorMonth": 32595, "sharesShortPreviousMonthDate": 1747267200, "dateShortInterest": 1749772800, "sharesPercentSharesOut": 0.0016, "heldPercentInsiders": 0.18431999, "heldPercentInstitutions": 0.15843001, "shortRatio": 0.16, "shortPercentOfFloat": 0.0016, "impliedSharesOutstanding": 2756990, "bookValue": -0.872, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -3324198, "trailingEps": -1.45, "lastSplitFactor": "1:10", "lastSplitDate": 1685923200, "52WeekChange": 0.23043478, "SandP52WeekChange": 0.12677538, "quoteType": "EQUITY", "currentPrice": 2.83, "recommendationKey": "none", "totalCash": 1384697, "totalCashPerShare": 0.516, "totalDebt": 0, "quickRatio": 3.899, "currentRatio": 4.264, "returnOnAssets": -0.81143, "returnOnEquity": -1.5513699, "freeCashflow": -1725609, "operatingCashflow": -2943794, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "LIXT", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1751576360, "regularMarketTime": 1751562001, "exchange": "NCM", "messageBoardId": "finmb_29181356", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 40.099, "regularMarketPrice": 2.83, "marketState": "CLOSED", "epsTrailingTwelveMonths": -1.45, "fiftyDayAverageChange": 1.5753999, "fiftyDayAverageChangePercent": 1.2556989, "twoHundredDayAverageChange": 1.1804999, "twoHundredDayAverageChangePercent": 0.71567136, "priceToBook": -3.2454128, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "shortName": "Lixte Biotechnology Holdings, I", "longName": "Lixte Biotechnology Holdings, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1193319000000, "postMarketChangePercent": -16.58657, "postMarketPrice": 2.3606, "postMarketChange": -0.46939993, "regularMarketChange": 0.81, "regularMarketDayRange": "2.4401 - 4.25", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1922516, "fiftyTwoWeekLowChange": 2.19, "fiftyTwoWeekLowChangePercent": 3.4218752, "fiftyTwoWeekRange": "0.64 - 4.25", "fiftyTwoWeekHighChange": -1.4200001, "fiftyTwoWeekHighChangePercent": -0.33411765, "fiftyTwoWeekChangePercent": 23.043478, "dividendDate": 1605830400, "earningsTimestamp": 1747053000, "earningsTimestampStart": 1754510400, "earningsTimestampEnd": 1754942400, "isEarningsDateEstimate": true, "displayName": "Lixte Biotechnology", "trailingPegRatio": null, "__fetch_time": "2025-07-05"}]